TITLE:
      Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)
SUMMARY:
      This prospective cohort study will provide information about: characteristics of Rivaroxaban
      use in patients who are prescribed Rivaroxaban for the first time compared to patients who
      are prescribed Phenprocoumon for the first time, the occurrence of intracranial haemorrhage,
      gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

          -  All male and female patients who have been prescribed for the first time either
             Rivaroxaban or standard of care from the date of market authorization of rivaroxaban
             to Dec 31, 2017

        Exclusion Criteria:

          -  Patients who have any record of being dispensed their index drug in the year before
             index date (i.e. cohort entry), or who qualify for both cohorts on the same day
